<DOC>
	<DOC>NCT00787618</DOC>
	<brief_summary>PK and safety profile of Proellex速 in females with various stages of impaired renal function</brief_summary>
	<brief_title>Evaluate PK and Safety of Proellex速 in Females With Various Stages of Impaired Renal Function and Healthy Females</brief_title>
	<detailed_description>The study will evaluate the pharmacokinetics and safety profile of Proellex速 in females with various stages of impaired renal function and in volunteers with normal renal function</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Speak, read, and understand English or Spanish and is willing and able to provide written informed consent on an IRBapproved form prior to the initiation of any study procedures; Female, between the ages of 18 and 48 years with Body Mass Index (BMI) between 18 and 39, inclusive, is preferred Subject must meet the criteria of mildly or moderately impaired renal function or have normal renal function Subject with renal impairment must have evidence of stable disease If on medications for treatment of the complications of renal disease, and other concommitant chronic illnesses, subject must have been taking the medications at a stable dose for at least 10 days prior to the first Proellex速 dosing date and are then to be continued at the same dose for the duration of the study. Negative urine pregnancy test at screening visit Subject must agree to use a medically acceptable and effective nonhormonal double barrier method of birth control Healthy subject must have no significant abnormal findings at the screening physical examination Subject is willing to remain in the clinic for the screening visit (approximately 1 day for the first screening visit) and for the treatment visit (approximately 3 days) Additional inclusion criteria may apply Abnormal screening visit vital signs or clinical laboratory evaluation considered clinically significant Subject with clinically significant abnormal liver function Pregnant or lactating females, or women who are attempting or expecting to become pregnant at any time during the study or one month after the study An acute illness within five (5) days of study medication administration Subject with diagnosed or suspected carcinoma of the breast, reproductive organs or any other organ system Additional exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Renal impairment</keyword>
</DOC>